RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Discovery of 3-(5-chloro-2-furoyl)-3,7-diazabicyclo[3.3.0]octane (TC-6683, AZD1446), a novel highly selective a4B2 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders
Mazurov, A., Miao, L., Bhatti, B., Strachan, J., Akireddy, S., Murthy, S., Kombo, D., Xiao, Y., Hammond, P., Zhang, J., Hauser, T., Jordan, K., Miller, C., Speake, J., Gatto, G., & Yohannes, D. (2012). Discovery of 3-(5-chloro-2-furoyl)-3,7-diazabicyclo[3.3.0]octane (TC-6683, AZD1446), a novel highly selective a4B2 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders. Journal of Medicinal Chemistry, 55(22), 9793 - 9809.
RTI shares its evidence-based research - through peer-reviewed publications and media - to ensure that it is accessible for others to build on, in line with our mission and scientific standards.